Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Phase 1 Recruiting
50 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Phase 1 Recruiting
300 enrolled
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Phase 1 Recruiting
36 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1 Recruiting
60 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Phase 1 Recruiting
45 enrolled
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 1 Recruiting
57 enrolled
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Phase 1 Recruiting
32 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Phase 1 Recruiting
240 enrolled
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
Phase 1 Recruiting
40 enrolled
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
Phase 1 Recruiting
62 enrolled
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Phase 1 Recruiting
36 enrolled
KOMODO-1
Phase 1 Recruiting
96 enrolled
HLD-0117
Phase 1 Recruiting
33 enrolled
CBD for Breast Cancer Primary Tumors
Phase 1 Recruiting
84 enrolled
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 Recruiting
162 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
PAveMenT
Phase 1 Recruiting
45 enrolled
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Phase 1 Recruiting
45 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Phase 1 Recruiting
136 enrolled
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Phase 1 Recruiting
64 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase 1 Recruiting
28 enrolled
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Phase 1 Recruiting
18 enrolled
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 Recruiting
150 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
CHANCES
Phase 1 Recruiting
27 enrolled
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 Recruiting
48 enrolled
OMNIRAY
Phase 1 Recruiting
421 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1 Recruiting
52 enrolled
Study of 68Ga-R10602
Phase 1 Recruiting
36 enrolled